PTPRF and cancer: While mostly conducted in EBC samples, these studies initially defined six biological subtypes (TNBCtype); the basal-like 1 and 2 (BL-1 & BL-2) groups characterised by high expression of cell cycle and DNA damage response genes; immunomodulatory (IM) cancers; mesenchymal-like and mesenchymal stem-like cancers (M & MSL) enriched for gene expression for epithelial-mesenchymal transition and growth factor pathways; and the luminal androgen receptor (LAR) subtype characterised by androgen receptor signalling [7].